logo-loader

Viking Therapeutics Inc rockets as H.C. Wainwright starts coverage

Last updated: 00:21 08 Apr 2016 AEST, First published: 19:21 07 Apr 2016 AEST

shutterstock_139366595
It also owns VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes.

Clinical-stage biopharmaceutical company Viking Therapeutics Inc (NASDAQ:VKTX) saw its shares rocket as broker H.C. Wainwright, which initiated coverage on the firm with a “Buy” recommendation.

The brokerage firm has set the target price of US$6 it reported in a research report released on Thursday, sending shares more than 63% higher to US$2.33.

Viking started the week with a market capitalisation of US$14mln, but after the rating was worth more than US$22.4mln, adding some US$8.4mln to the company’s value.

The Company is focused on the development of therapies for metabolic and endocrine disorders.

Its lead program, VK5211, is an orally available drug candidate under a Phase II clinical trial.

The firm is also developing VK2809 and VK0214 for the treatment and potential prophylaxis of genetic disorderALD.

It also owns VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes. 

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

2 hours, 14 minutes ago